American Biogenetic Sciences, Inc. - Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Net loss	$ (69,620)	$ (77,016)
Expenses paid by issuance of common stock	0	0
Fair value of services provided by related parties	56,000	61,000
Increase (decrease) in accounts payable and accrued expenses	11,120	13,016
Cash flows used by operating activities	(2,500)	(3,000)
Cash used in investing activities	0	0
Procceds from related party borrowings	2,500	3,000
Cash generated by financing activities	2,500	3,000
Change in cash	$ 0	$ 0